30 May 2018 EMA/HMPC/370139/2018 Inspections, Human Medicines Pharmacovigilance & Committees Division

Committee on Herbal Medicinal Products (HMPC) Agenda for the meeting on 04-05 June 2018

Chair: Marisa Delbò

Vice-Chair: Emiel Van Galen

04 June 2018, 14:00 – 19:00, 2F 05 June 2018, 09:00 – 13:00, 2F

Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. Of note, this agenda is a working document primarily designed for HMPC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Table of contents 1.

Introduction

1.1.

Welcome and declarations of interest of members, alternates and experts ............ 4

1.2.

Adoption of agenda................................................................................................. 4

1.3.

Adoption of the minutes ......................................................................................... 4

2.

European Union herbal monographs and list entries

2.1.

Report on MLWP activities ...................................................................................... 4

2.1.1.

Appointment of Rapporteurs and Peer-reviewers ........................................................... 4

2.1.2.

Report from the MLWP March 2018 meeting .................................................................. 4

2.2.

Revised EU herbal monographs and list entries for final adoption .......................... 4

2.2.1.

Monograph on Curcumae longae rhizoma and supporting documents ............................... 4

2.2.2.

Monograph on Echinaceae pallidae radix and supporting documents................................. 4

2.2.3.

Monograph on Oenotherae biennis oleum and supporting documents ............................... 5

2.2.4.

Monograph on Pelargonii radix and supporting documents .............................................. 5

2.3.

Revised EU herbal monographs and list entries for public consultation .................. 5

2.4.

EU herbal monographs, list entries and public statements for final adoption ......... 5

2.4.1.

Public statement on Glycini semen and supporting documents......................................... 5

2.4.2.

Monograph on Silybi mariani fructus and supporting documents ...................................... 5

2.5.

EU herbal monographs, list entries and public statements for adoption for release for public consultation ............................................................................................ 5

2.5.1.

Monograph on Malvae folium and supporting documents ................................................ 5

2.5.2.

Monograph on Malvae flos and supporting documents .................................................... 5

2.6.

Reviewed EU herbal monographs and list entries for decision on revision.............. 5

2.6.1.

Monograph on Hippocastani semen and supporting documents ........................................ 5

2.6.2.

Monograph on Polypodii rhizoma and supporting documents ........................................... 6

3.

Referral procedures

6

4.

Guidelines and guidance documents

6

4.1.

Non-clinical/clinical safety and efficacy and multidisciplinary ................................ 6

4.1.1.

Guideline on non-clinical documentation in applications for marketing authorisation/registration of well- established and traditional herbal medicinal products (EMEA/HMPC/32116/2005 Rev.1) ................................................................................ 6

4.1.2.

Public statement on the use of herbal medicinal products containing estragole .................. 6

4.2.

Quality .................................................................................................................... 6

4.2.1.

Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products (EMA/HMPC/162241/2005 Rev. 3) ............................................................................... 6

4.2.2.

Guideline on quality of herbal medicinal products/traditional herbal medicinal products (EMA/HMPC/201116/2005 Rev. 3) ............................................................................... 6

4.3.

Regulatory / Procedural ......................................................................................... 6

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

4

4

Page 2/10

4.3.1.

Procedure for the review and revision of European Union herbal monographs and European Union list entries (EMA/HMPC/124695/2011 Rev.2) ....................................................... 6

4.4.

Report on HMPC Drafting Groups activities ............................................................. 7

4.4.1.

Quality DG ................................................................................................................ 7

4.4.2.

ORGAM DG ............................................................................................................... 7

5.

Organisational, regulatory and methodological matters

5.1.

Mandate and organisation of the HMPC .................................................................. 7

5.1.1.

Relocation Preparedness to CxMPs – cancelled .............................................................. 7

5.1.2.

Update on the EMA relocation ..................................................................................... 7

5.1.3.

Strategic Review and Learning Meetings ....................................................................... 7

5.2.

Coordination with EMA Scientific Committees or CMDh-v ....................................... 8

5.2.1.

Scientific Coordination Board Meeting........................................................................... 8

5.3.

Coordination with EMA Working Parties/Working Groups/Drafting Groups ........... 8

5.4.

Cooperation within the EU regulatory network ....................................................... 8

5.4.1.

Coordination with the European Commission ................................................................. 8

5.4.2.

Coordination with European Pharmacopoeia .................................................................. 8

5.5.

Cooperation with International Regulators............................................................. 8

5.6.

Contacts of the HMPC with external parties and interaction with the Interested Parties to the Committee ........................................................................................ 8

5.6.1.

Question on HMPC assessment and national monograph use ........................................... 8

5.7.

Work plan ............................................................................................................... 8

5.7.1.

HMPC work plan 2018 ................................................................................................ 8

5.8.

Planning and reporting ........................................................................................... 9

5.9.

Legislation and regulatory affairs ........................................................................... 9

5.9.1.

WEU/Bibliographic application regarding Art. 10a Dir. 2001/83/EC for HMPs – Reference to other products........................................................................................................... 9

6.

Any other business

6.1.

Topics for discussion .............................................................................................. 9

6.1.1.

Questions from NCAs on Public statement on pyrrolizidine alkaloid contaminations ............ 9

6.2.

Documents for information ..................................................................................... 9

6.2.1.

HMPC ....................................................................................................................... 9

6.2.2.

MLWP ....................................................................................................................... 9

6.2.3.

ARSP........................................................................................................................ 9

6.2.4.

Other ..................................................................................................................... 10

6.2.5.

Guideline on quality of water for pharmaceutical use (EMA/150605/2018) ...................... 10

6.2.6.

Feedback on national experiences with HMPC monographs and guidelines ...................... 10

6.2.7.

EU – India/AYUSH communication ............................................................................. 10

6.2.8.

Request from NL regarding products on the EU market containing Erythrina mulungu Mart. Ex Benth (Erythrina verna Vell) ................................................................................. 10

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

7

9

Page 3/10

1.

Introduction

1.1.

Welcome and declarations of interest of members, alternates and experts Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the HMPC plenary session to be held on 04-05 June 2018. See June 2018 HMPC minutes (to be published post July 2018 HMPC meeting).

1.2.

Adoption of agenda HMPC agenda for 04-05 June 2018 Time schedule for 04-05 June 2018

1.3.

Adoption of the minutes HMPC minutes for 26-27 March 2018

2.

European Union herbal monographs and list entries

2.1.

Report on MLWP activities

2.1.1.

Appointment of Rapporteurs and Peer-reviewers Changes of Rapporteurs for PS review Adhatoda vasica folium Andrographidis paniculatae folium Angelicae sinensis radix Centellae asiaticae herba Withaniae somniferae radix

2.1.2.

Report from the MLWP March 2018 meeting Report: MLWP Chair/MLWP Vice-Chair Action: for information Document: Draft minutes for the MLWP meeting on 28-29 March 2018

2.2.

Revised EU herbal monographs and list entries for final adoption

2.2.1.

Monograph on Curcumae longae rhizoma and supporting documents Action: for adoption Documents: MO, AR, LoR; References: 00/132

2.2.2.

Monograph on Echinaceae pallidae radix and supporting documents Action: for adoption Documents: MO, AR, LoR; References: 59/62

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

Page 4/10

2.2.3.

Monograph on Oenotherae biennis oleum and supporting documents Action: for adoption Documents: MO, AR, LoR; References: 61/106

2.2.4.

Monograph on Pelargonii radix and supporting documents Action: for adoption Documents: MO, AR, LoR, OoC MO, OoC AR; References: 99/96; New references

2.3.

Revised EU herbal monographs and list entries for public consultation None

2.4.

EU herbal monographs, list entries and public statements for final adoption

2.4.1.

Public statement on Glycini semen and supporting documents Action: for adoption Documents: PS, AR, LoR; References: 52/49

2.4.2.

Monograph on Silybi mariani fructus and supporting documents Action: for discussion Documents: MO, AR, LoR, OoC, Presentation

2.5.

EU herbal monographs, list entries and public statements for adoption for release for public consultation

2.5.1.

Monograph on Malvae folium and supporting documents Action: for adoption Documents: MO, AR, LoR, OoC; References: 149/119

2.5.2.

Monograph on Malvae flos and supporting documents Action: for adoption Documents: MO, AR, LoR, OoC; References: 149/119

2.6.

Reviewed EU herbal monographs and list entries for decision on revision

2.6.1.

Monograph on Hippocastani semen and supporting documents Action: for adoption Document: Review outcome; References: 07/08

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

Page 5/10

2.6.2.

Monograph on Polypodii rhizoma and supporting documents Action: for adoption Document: Review outcome; References: 00/00

3.

Referral procedures None

4.

Guidelines and guidance documents

4.1.

Non-clinical/clinical safety and efficacy and multidisciplinary

4.1.1.

Guideline on non-clinical documentation in applications for marketing authorisation/registration of well- established and traditional herbal medicinal products (EMEA/HMPC/32116/2005 Rev.1) Action: for adoption Documents: Guideline, OoC

4.1.2.

Public statement on the use of herbal medicinal products containing estragole Action: for discussion Documents: Draft revised PS, OoC

4.2.

Quality

4.2.1.

Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products (EMA/HMPC/162241/2005 Rev. 3) Report: Q DG Chair Action: for adoption Documents: Draft revised Guideline

4.2.2.

Guideline on quality of herbal medicinal products/traditional herbal medicinal products (EMA/HMPC/201116/2005 Rev. 3) Report: Q DG Chair Action: for adoption Documents: Draft revised Guideline

4.3.

Regulatory / Procedural

4.3.1.

Procedure for the review and revision of European Union herbal monographs and European Union list entries (EMA/HMPC/124695/2011 Rev.2) Action: for adoption Documents: Draft procedure; Review template; Addendum template

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

Page 6/10

4.4.

Report on HMPC Drafting Groups activities

4.4.1.

Quality DG Report: Q DG Chair •

Meeting report from Q DG virtual meeting held on 19 Apr 2018 Action: for adoption Document: Meeting report



Draft agenda for the Q DG virtual meeting to be held 21 Jun 2018 Action: for information Document: Draft agenda

4.4.2.

ORGAM DG Report: ORGAM DG Chair •

Meeting report from ORGAM DG virtual meeting held on 23 Apr 2018 Action: for adoption Document: Meeting report



Agenda ORGAM DG meeting to be held on 19 Jun 2018 Action: for information Document: Draft agenda



Appointment for new member at ORGAM DG Action: for adoption ORGAM mandate; Candidature

5.

Organisational, regulatory and methodological matters

5.1.

Mandate and organisation of the HMPC

5.1.1.

Relocation Preparedness to CxMPs – cancelled

5.1.2.

Update on the EMA relocation Action: for information Document: Presentation

5.1.3.

Strategic Review and Learning Meetings Austria Presidency meeting – Vienna, 15-17 Oct 2018 Action: for discussion Document: Revised Agenda

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

Page 7/10

5.2.

Coordination with EMA Scientific Committees or CMDh-v

5.2.1.

Scientific Coordination Board Meeting Report: HMPC Chair Action: for information Documents: Minutes 12 March 2018; Agenda 3 May 2018

5.3.

Coordination with EMA Working Parties/Working Groups/Drafting Groups None

5.4.

Cooperation within the EU regulatory network

5.4.1.

Coordination with the European Commission •

Clarification of classification on Saccharomyces cerevisiae CBS 5926



AESGP proposal on the simplification of variations specific to herbal medicinal product

Action: for discussion Action: for discussion Document: QDG proposal

5.4.2.

Coordination with European Pharmacopoeia •

EDQM 13A expert group meetings Action: for information



EDQM 13B expert group meetings Action: for information



EDQM TCM expert group meetings Action: for information



EDQM PA working party Action: for information

5.5.

Cooperation with International Regulators None

5.6.

Contacts of the HMPC with external parties and interaction with the Interested Parties to the Committee

5.6.1.

Question on HMPC assessment and national monograph use Report: HMPC Chair Action: for adoption

5.7.

Work plan

5.7.1.

HMPC work plan 2018 Report: HMPC Chair

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

Page 8/10

Action: for information Document: Work plan 2018 – current status June 2018

5.8.

Planning and reporting None

5.9.

Legislation and regulatory affairs

5.9.1.

WEU/Bibliographic application regarding Art. 10a Dir. 2001/83/EC for HMPs – Reference to other products Report: HMPC Chair Action: for discussion

6.

Any other business

6.1.

Topics for discussion

6.1.1.

Questions from NCAs on Public statement on pyrrolizidine alkaloid contaminations Action: for adoption Documents: Summarised responses to questions from BE & NL; Literature

6.2.

Documents for information

6.2.1.

HMPC Table of Decisions from HMPC meeting held on 26-27 March 2018 Overview of expertise of members HMPC and subgroups Meeting report from HMPC meeting held on 27-28 March 2018 Overview of status of HMPC assessment work – priority list Inventory of herbal substances for assessment work Abbreviations in HMPC agendas/minutes Common names of herbal substances in all languages

6.2.2.

MLWP •

Overview of status of HMPC/MLWP assessment work



Draft agenda of MLWP meeting to be held on 05-07 June 2018

6.2.3.

ARSP •

English template



English summaries for publication: •

Black cohosh



Agnus castus

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

Page 9/10

6.2.4.



Calendula



Elder flower



Mullein flower

Other •

EU herbal monographs, list entries and public statements post adoption Remaining publication delays:





o

Allii sativi bulbus

o

Pistacia lentiscus (mastix)

o

Cynarae folium

Conference on 6 June: Reducing the need for antibiotics – The contribution of Complementary and Alternative Medicine

6.2.5.

Guideline on quality of water for pharmaceutical use (EMA/150605/2018) Documents: Guideline; Concept paper, HMPC comments provided 26 April 2018

6.2.6.

Feedback on national experiences with HMPC monographs and guidelines •

draft template



summary feedback, examples feedback received

6.2.7.

EU – India/AYUSH communication

6.2.8.

Request from NL regarding products on the EU market containing Erythrina mulungu Mart. Ex Benth (Erythrina verna Vell) Document: NL questions to all HMPC members

Committee on Herbal Medicinal Products (HMPC) EMA/HMPC/370139/2018

Page 10/10

HMPC Agenda 04-05 June 2018 - European Medicines Agency

Jun 5, 2018 - Some of the information contained in this agenda is considered ... access to documents within the framework of Regulation (EC) No 1049/2001 ...

158KB Sizes 0 Downloads 184 Views

Recommend Documents

HMPC Agenda 29-30 January 2018 - European Medicines Agency
Jan 25, 2018 - Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decisio

DRAFT COMP Agenda 19-21 June 2018 - European Medicines Agency
2 days ago - Draft agenda for the meeting on 19-21 June 2018. Chair: Bruno ... be published in the COMP meeting reports once the procedures are finalised. Of note ...... products at time marketing authorisation extension. 24. 5.1. .... List of all ap

June 2018 - European Medicines Agency - Europa EU
Jun 22, 2018 - An agency of the European Union. Telephone +44 (0)20 ... Selumetinib for treatment of neurofibromatosis type 1, AstraZeneca AB;. •. Synthetic ...

Agenda - European Medicines Agency - europa.eu
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...

Agenda - European Medicines Agency - europa.eu
Sep 8, 2016 - 3-year report on Pharmacovigilance activities. Helen Lee, European Commission. •. Scanning the horizon for 2016 – 2018. Peter Arlett, EMA.

Agenda - European Medicines Agency - europa.eu
Jun 18, 2018 - 27. 7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of .... 5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one, EMA/OD/031/10 Glutathione-pegylated ...... Abbreviations / Acronyms.

Agenda - European Medicines Agency veterinary medicines ...
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

Agenda - European Medicines Agency - Europa EU
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.

Agenda - European Medicines Agency - Europa EU
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs – meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju

Agenda - European Medicines Agency - Europa EU
Jun 26, 2018 - oxadiazole-3-carboximidamide - EMEA-002072-PIP01-16-M01 . ..... Human alpha-galactosidase A - Orphan - EMEA-001828-PIP01-15-M01 .

Agenda - European Medicines Agency - Europa EU
Jul 16, 2018 - Cladribine, EMA/OD/087/17 Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8. 2.2.6. - EMA/OD/098/18. Treatment of ...

Agenda - European Medicines Agency - Europa EU
Feb 9, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. •. Product

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri

Agenda - European Medicines Agency - Europa EU
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina Schüßler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g

Agenda - European Medicines Agency - Europa EU
Dec 7, 2016 - publication of clinical data (Policy 0070) and revisions to the guidance to industry – Industry Associations Webinar. 9 December 2016, 10:00 to ...

Agenda of January 2018 CVMP meeting - European Medicines Agency
Jan 16, 2018 - framework of Regulation (EC) No 1049/2001 on access to documents because they are subject to on- going procedures for ... Co-rapp: C. Muñoz. For decision: Need for oral explanation. For adoption: Scientific overview and list of outsta

Agenda - European Medicines Agency - Europa EU
Sep 19, 2017 - 14:00-14:05. 2. Data integrity – early signal detection. - data patterns/trends in data ... 16:20-17:00. 5. Inspections of Ligand Binding Assays (in.

Agenda - European Medicines Agency - Europa EU
Nov 7, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union. Telephone ...... Visualisation of choline metabolism in malignant neoplasms ..... A paediatric investigation plan (PIP) is a dev

Agenda - European Medicines Agency - Europa EU
Jan 23, 2018 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be

Agenda - European Medicines Agency - Europa EU
Oct 24, 2017 - Application of Article 8(2) of the Orphan Regulation ..... propoxy)-phenyl]-methanone, EMA/OD/187/14 Herpes simplex type 1 virus containing.

Agenda - European Medicines Agency - Europa EU
Jun 14, 2016 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ... EMA initiatives to support and accelerate early access. 10:00 2.1 ...

Agenda - Patient Registries Workshop - European Medicines Agency
Oct 18, 2016 - Send a question via our website www.ema.europa.eu/contact ... marketing authorisation holder (MAH) to create a new registry based on a ...

Agenda - European Medicines Agency - Europa EU
6 days ago - EMA/OD/103/14 Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment, EMA/OD/175/14 Allogeneic ...